CZ294094B6 - }SB@}FenylacetamidoB@}@pyridylBpropionová kyselina a způsob její připravy - Google Patents

}SB@}FenylacetamidoB@}@pyridylBpropionová kyselina a způsob její připravy Download PDF

Info

Publication number
CZ294094B6
CZ294094B6 CZ20021311A CZ20021311A CZ294094B6 CZ 294094 B6 CZ294094 B6 CZ 294094B6 CZ 20021311 A CZ20021311 A CZ 20021311A CZ 20021311 A CZ20021311 A CZ 20021311A CZ 294094 B6 CZ294094 B6 CZ 294094B6
Authority
CZ
Czechia
Prior art keywords
pyridyl
phenylacetamido
propionic acid
formula
general formula
Prior art date
Application number
CZ20021311A
Other languages
English (en)
Inventor
Costanzoámichaeláj
Hoekstraáwilliamáj
Maryanoffábruceáe
Original Assignee
Ortho@Mcneilápharmaceuticalźáinc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho@Mcneilápharmaceuticalźáinc filed Critical Ortho@Mcneilápharmaceuticalźáinc
Publication of CZ294094B6 publication Critical patent/CZ294094B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

}SB@}FenylacetamidoB@}@pyridylBpropionová kyselina vzorce AG@ a způsob její přípravyŹ při němž se @}fenylacetamidoB@}@pyridylBpropionová kyselina vzorce AG@ nechá reagovat s penicilinamidázouŹ výhodně takŹ že se penicilinamidázou působí na vodný roztok sloučeniny vzorce AG@Ź jehož hodnota pH byla předběžně nastavena na asi @ŹQ@ Kyselina vzorce AG@ slouží jako meziprodukt pro přípravu karboxamidových derivátů pyrrolidinuŹ piperidinu a hexahydroazepinuŹ které mohou být použity jako léčiva pro léčení trombotických poruch zprostředkovaných destičkamiŕ

Description

Oblast techniky
Vynález se týká (S)-3-(fenylacetamido)-3-(3-pyridyl)-propionové kyseliny a způsobu její přípravy. Tato kyselina slouží jako meziprodukt pro přípravu karboxamidových derivátů pyrrolidinu, piperidinu a hexahydroazepinu. Posledně uvedené sloučeniny mohou být použity jako léčiva pro léčení trombotických poruch zprostředkovaných destičkami.
Dosavadní stav techniky
Racemickou 3-(fenylacetamido)-3-(3-pyridyl)propionovou kyselinu je možno připravit podle E. Profft, J, Prakt. Chem. 1965, 30, 18. Její S-enantiomer, který je předmětem tohoto vynálezu však dosud nebyl popsán.
Podstata vynálezu
Předmětem vynálezu je (S)-3-(fenyIacetamido)-3-(3-pyridyl)propionová kyselina vzorce AG4
(AG4)
Dalším předmětem vynálezu je také způsob výroby sloučeniny AG4, jehož podstata spočívá v tom, že se 3-(fenylacetamido)-3-(3-pyridyl)propionová kyselina vzorce AG3
(AG3) nechá reagovat s penicilinamidázou.
Ve výhodném provedení tohoto způsobu se postupuje tak, že se se penicilinamidázou působí na vodný roztok sloučeniny vzorce AG3, jehož hodnota pH byla předběžně nastavena na asi 7,5.
Výchozí 3-(fenylacetamido)-3-(3-pyridyl)propionová kyselina vzorce AG3 se připravuje za použití modifikovaného Knoevanagelova postupu (schéma AG; E. Profft, J. Prakt. Chem. 1965, 30, 18). Kyselina vzorce AG3 se způsobem podle vynálezu obohatí o S-enantiomer selektivním štěpením pomocí penicilinamidázy (V. A. Soloshonok, Tetrahedron:Asymmetry 1965, 6, 1601).
-1 1
Nežádoucí R-enantiomer se pomocí amidázy hydrolyzuje, zatímco S-enantiomer si udrží fenylacetylovou skupinu.
Schéma AG
CH2(CO2H)2
NH4OAc
EtOHrcflux
PhCH2COCl
EtjN, vodný aceton
H
AG3
Penícilinamídáza pH7,5 (aq.)
Kyselina vzorce AG4 slouží jako meziprodukt pro přípravu karboxamidových derivátůpyrrolidonu, piperidinu a hexahydroazepinu obecného vzorce I:
ť (CH^-A (l) kde:
A je zvolen ze souboru zahrnujícího 2-piperidyl, 3—piperidyl, 4-piperidyl, 1-piperazinyl, 2-pyrrolidinyl, 3-pyrrolidinyl a NHR2;
R2 je zvolen ze souboru zahrnujícího H, alkyl s 1 až 8 atomy uhlíku a acyl se 2 až 6 atomy uhlíku a přednostně znamená vodík;
m je celé číslo 1, 2 nebo 3 a přednostně znamená 1 nebo 2;
X je zvolen ze souboru zahrnujícího C(O), C(O)O, C(O)NH, CH2 a SO2;
n je celé číslo 1, 2 nebo 3;
R1 je zvolen ze souboru zahrnujícího vodík a cykloalkyl s 5 až 8 atomy uhlíku;
Y je zvolen ze souboru zahrnujícího (CH2)P, CH(R3)(CH2)q, (CH2)qCH(R3), (CH(COR4)CH2)q, (CH2)qCHOH a 3-piperidinkarboxylovou kyselinu; s výhradou, že když Y je (CH2)P a p je 2, X je jiný než C(O), nebo když X je C(O), potom buď R1 je jiný než H, nebo R2 je jiný než H, a s další výhradou, že když X je (CH(CO2R4)CH2)q, X je jiný než C(O) nebo CH2;
p je 2 nebo 3;
q je 1, 2 nebo 3 a přednostně 1;
R3 je alkyl s 1 až 8 atomy uhlíku, alkenyl se 2 až 8 atomy uhlíku, alkinyl se 2 až 8 atomy uhlíku, fenyl, naftyl, fenylalkyl s 1 až 8 atomy uhlíku v alkylové části, naftylalkyl s 1 až 8 atomy uhlíku v alkylové části nebo heteroaryl, kterým může být pyridyl, thienyl, furyl, nebo chinolyl;
R4 je vodík nebo alkyl s 1 až 8 atomy uhlíku nebo cykloalkyl s 5 až 8 atomy uhlíku a přednostně znamená vodík;
Z je CO2H, CO2alkyl, SO3H, PO3H2 nebo 5-tetrazol.
Sloučeniny obecného vzorce I, které jsou předmětem základního patentu, jsou inhibitory agregace destiček a jako takové jsou užitečné při léčbě trombotických poruch zprostředkovaných destičkami, jako je arteriální a venózní trombóza, akutní infarkt myokardu, nestabilní angína, reokluze následující trombolytickou terapii a angioplastiku, zápal a různé vazookluzivní poruchy. Tyto sloučeniny jsou užitečné také jako antitrombotická činidla použitá v souvislosti s fibrinolytickou terapií (například t-PA nebo streptokináza).
Přiklad provedení vynálezu (S)-3-(Fenylacetamido)-3-(3-pyridyl)propionová kyselina
3-(Fenylacetamido)-3-(3-pyridyl)propionová kyselina vzorce AG3 se připraví za použití standardních způsobů, jak jsou znázorněny ve schématu AG (E. Profft, J. Prakt. Chem. 1965, 30, 18). Roztok sloučeniny AG3 (0,225 mol) ve vodě (600 ml) se při teplotě místnosti nastaví na pH 7,5 za použití KOH (3,0 N) a nechá reagovat s penicilinamidázou (91 502 jednotek, Sigma). Tato směs se míchá 47 hodin, okyselí na pH 1 pomocí HC1 (konc.) a výsledná sraženina se odfiltruje přes celatom FW-14. Filtrát se extrahuje Et2O (3 x 300 ml) a zkoncentruje ve vakuu.
PATENTOVÉ NÁROKY

Claims (3)

  1. PATENTOVÉ NÁROKY
    1. (S)-3-(Fenylacetamido)-3-(3-pyridyl)propionová kyselina vzorce AG4 (AG4)
  2. 2. Způsob přípravy (S)-3-(fenylacetamido)-3-(3-pyridyl)-propionové kyseliny vzorce AG4, vyznačující se tím, že 3-(fenylacemitado)-3-(3-pyridyl)propionová kyselina vzorce AG3 (AG3) nechá reagovat s penicilinamidázou.
  3. 3. Způsob podle nároku 2, v y z n a č u j í c í se tím, že se se penicilinamidázou působí na vodný roztok sloučeniny vzorce AG3, jehož hodnota pH byla předběžně nastavena na 7,5.
    Konec dokumentu
CZ20021311A 1996-05-01 1997-04-29 }SB@}FenylacetamidoB@}@pyridylBpropionová kyselina a způsob její připravy CZ294094B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1667596P 1996-05-01 1996-05-01

Publications (1)

Publication Number Publication Date
CZ294094B6 true CZ294094B6 (cs) 2004-10-13

Family

ID=21778348

Family Applications (2)

Application Number Title Priority Date Filing Date
CZ20021311A CZ294094B6 (cs) 1996-05-01 1997-04-29 }SB@}FenylacetamidoB@}@pyridylBpropionová kyselina a způsob její připravy
CZ19983488A CZ293912B6 (cs) 1996-05-01 1997-04-29 Karboxamidový derivát pyrrolidinuŹ piperidinu hexahydroazepinuŹ jeho použití a farmaceutická kompozice na jeho bázi

Family Applications After (1)

Application Number Title Priority Date Filing Date
CZ19983488A CZ293912B6 (cs) 1996-05-01 1997-04-29 Karboxamidový derivát pyrrolidinuŹ piperidinu hexahydroazepinuŹ jeho použití a farmaceutická kompozice na jeho bázi

Country Status (26)

Country Link
US (1) US6069254A (cs)
EP (2) EP0923555B1 (cs)
JP (1) JP4328387B2 (cs)
KR (1) KR100510854B1 (cs)
CN (1) CN1286684A (cs)
AT (2) ATE421952T1 (cs)
AU (1) AU726594B2 (cs)
BG (1) BG64276B1 (cs)
BR (1) BR9710434A (cs)
CA (1) CA2258701C (cs)
CZ (2) CZ294094B6 (cs)
DE (2) DE69739239D1 (cs)
DK (1) DK0923555T3 (cs)
EE (1) EE03823B1 (cs)
ES (3) ES2320316T3 (cs)
GE (1) GEP20002187B (cs)
HK (1) HK1041406A1 (cs)
NZ (1) NZ332585A (cs)
PL (1) PL190796B1 (cs)
PT (1) PT923555E (cs)
RU (1) RU2194038C2 (cs)
SK (1) SK149798A3 (cs)
TR (1) TR199802207T2 (cs)
UA (1) UA70285C2 (cs)
WO (1) WO1997041102A1 (cs)
YU (1) YU48698A (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066651A (en) * 1997-10-29 2000-05-23 Ortho-Mcneil Pharmaceutical, Inc. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
JP2002540101A (ja) 1999-03-22 2002-11-26 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド プロピオン酸３−アミノ−３−アリールの合成
HUP0201262A3 (en) * 1999-03-22 2003-12-29 Ortho Mcneil Pharm Inc Process for preparing [s-(r*,s*)]-betha-[[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinepropanoic acid and derivatives
CA2367969A1 (en) * 1999-03-22 2000-09-28 Ortho-Mcneil Pharmaceutical, Inc. Process of preparing 3s-3-amino-3-aryl propionic acid and derivatives thereof
BR0007183A (pt) * 1999-09-29 2002-02-05 Ortho Mcneil Pharm Inc Isonipectoamidas para o tratamento de distúrbios mediados por integrina
AUPQ570100A0 (en) * 2000-02-17 2000-03-09 Fujisawa Pharmaceutical Co., Ltd. Beta-alanine derivatives and their use as receptor antagonists
SE0001803D0 (sv) * 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
WO2002081467A1 (en) * 2001-04-09 2002-10-17 Ortho-Mcneil Pharmaceutical, Inc. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
WO2004007444A2 (en) 2002-07-11 2004-01-22 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
CA2558064A1 (en) 2004-02-25 2005-09-01 Astellas Pharma Inc. Contrast medium for thrombus formation
RU2393154C2 (ru) 2004-03-24 2010-06-27 Йерини Аг Новые соединения для ингибирования ангиогенеза и их применение
CA2584502A1 (en) 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
JP2008504275A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション Ｎ−置換ピペリジンおよびその医薬としての使用
TW200720252A (en) * 2005-05-27 2007-06-01 Sankyo Co Cyclic amine derivative having substituted alkyl group
WO2008106202A1 (en) * 2007-02-27 2008-09-04 Housey Gerard M Theramutein modulators
US8207298B2 (en) 2008-05-01 2012-06-26 Archemix Corp. Methods of separating biopolymer conjugated molecules from unconjugated molecules
PL2501693T3 (pl) * 2009-11-18 2015-03-31 Fab Pharma Sas Azaheterocykliczne akryloamidy i ich zastosowanie jako środków bakteriobójczych
ES2621379T3 (es) * 2011-08-17 2017-07-03 Piramal Imaging Sa Compuestos para la unión a la glicoproteína IIb/IIIa específica de las plaquetas y su utilización para la formación de imágenes de trombos
EP2956461A1 (en) 2013-02-12 2015-12-23 Bayer Pharma Aktiengesellschaft Metal chelate compounds for binding to the platelet specific glycoprotein iib/iiia
EA033342B1 (ru) * 2015-07-08 2019-09-30 Ресерч Энд Бизнес Фондэйшн Сонгюнгван Юниверсити Пирролидинкарбоксамидо производные и способы их получения и их применение
KR102058853B1 (ko) 2018-02-28 2019-12-24 브릿지바이오테라퓨틱스(주) 지질화 펩타이드의 수용성 염과 이의 제조 방법 및 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR851819B (cs) * 1984-08-17 1985-11-26 Wyeth John & Brother Ltd
DE3435156A1 (de) * 1984-09-25 1986-04-03 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung der stereoisomeren von 1-amino-alkylphosphonsaeuren oder 1-aminoalkylphosphinsaeuren
EP1106606A3 (en) * 1993-09-22 2003-10-22 Fujisawa Pharmaceutical Co., Ltd. N-(3-piperidinylcarbonyl)-beta-alanine derivatives as paf antagonists
WO1995011228A1 (fr) * 1993-10-19 1995-04-27 Sumitomo Pharmaceuticals Co., Ltd. Derive d'acide 2,3-diaminopropionique
US5770575A (en) * 1994-03-16 1998-06-23 Ortho Pharmaceutical Corporation Nipecotic acid derivatives as antithrombotic compounds
US5639765A (en) * 1995-01-17 1997-06-17 G. D. Searle & Co. Guanidinoalkyl glycine β-amino acids useful for inhibiting bone loss
KR19980703107A (ko) * 1995-03-17 1998-10-15 후지야마 아키라 N-아실피페리디닐카보닐아미노카복실산 및 당단백질 IIB/IIa 길항제와 피브리노겐-혈소판 결합 억제제로서의 이의 용도

Also Published As

Publication number Publication date
CA2258701C (en) 2008-02-12
ES2320316T3 (es) 2009-05-21
KR20000065163A (ko) 2000-11-06
RU2194038C2 (ru) 2002-12-10
WO1997041102A1 (en) 1997-11-06
UA70285C2 (en) 2004-10-15
PL329695A1 (en) 1999-04-12
KR100510854B1 (ko) 2006-05-12
CA2258701A1 (en) 1997-11-06
BG64276B1 (bg) 2004-08-31
GEP20002187B (en) 2000-07-25
EP1988078B1 (en) 2012-10-17
DE69739239D1 (de) 2009-03-19
ES2396725T3 (es) 2013-02-25
TR199802207T2 (xx) 2001-06-21
PT923555E (pt) 2005-09-30
JP2000510111A (ja) 2000-08-08
EP1988078A1 (en) 2008-11-05
CZ293912B6 (cs) 2004-08-18
BG102966A (en) 1999-11-30
DE69733565D1 (de) 2005-07-21
DE69733565T2 (de) 2006-05-11
EE03823B1 (et) 2002-08-15
HK1041406A1 (en) 2002-07-05
CN1286684A (zh) 2001-03-07
BR9710434A (pt) 1999-08-17
JP4328387B2 (ja) 2009-09-09
EP0923555A1 (en) 1999-06-23
EP0923555B1 (en) 2005-06-15
CZ348898A3 (cs) 1999-08-11
NZ332585A (en) 2000-04-28
ATE297894T1 (de) 2005-07-15
DK0923555T3 (da) 2005-08-15
US6069254A (en) 2000-05-30
ES2243996T3 (es) 2005-12-01
ATE421952T1 (de) 2009-02-15
AU726594B2 (en) 2000-11-16
SK149798A3 (en) 1999-10-08
EE9800371A (et) 1999-04-15
YU48698A (sh) 2001-09-28
AU2816697A (en) 1997-11-19
PL190796B1 (pl) 2006-01-31

Similar Documents

Publication Publication Date Title
CZ294094B6 (cs) }SB@}FenylacetamidoB@}@pyridylBpropionová kyselina a způsob její připravy
HU913396D0 (en) Process for the production of azasteroide compounds and medical preparations containing them as active agents
HUT46708A (en) Process for producing heterocyclic ketones and pharmaceutical compositions containing them as active components
JPH06247963A (ja) フィブリノーゲン受容体拮抗薬
JP3388803B2 (ja) 光学活性７−アミジノナフタレン誘導体の製造法
CA2289409A1 (en) Sulfoxide compounds and acetone complexes, and a process for producing the same
HUP0000728A2 (hu) Naftiridinkarbonsavszármazék sója, eljárás előállítására és a vegyületet tartalmazó gyógyászati készítmény
EP1147085B1 (en) Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors
AT379800B (de) Verfahren zur herstellung von neuen 2-oxazetidin-derivaten
KR20240157703A (ko) 디-시클로프로필 기재 il-17a 조정제 및 그의 용도
JP4491135B2 (ja) ２−置換ピペリジン立体異性体を製造するための方法及び中間体
JP2000053642A (ja) ３―アミノ―ピロリジン誘導体の製造方法
KR880700793A (ko) 퀴놀린 카복실산의 제조 방법
ATE124687T1 (de) Verfahren zur herstellung von chinolincarbonsäuren.
JPH0283371A (ja) Ｎ，ｎ’‐ビス（アルコキシアルキル）‐ピリジン‐２，４‐ジカルボキサミドの製造方法
DK623486D0 (da) Guanidinobenzoesyreesterderivater, fremgangsmaade til deres fremstilling og farmaceutiske kompositioner indeholdende forbindelserne
WO1996013497A1 (fr) Derive de tetrahydroisoquinoleine et preparation medicinale contenant ce derive
GB8415615D0 (en) Preparing azetidine derivatives
ATE286048T1 (de) Verfahren zur herstellung von carbostyril- derivaten
Baba et al. Asymmetric reduction of iminium salt with chiral dihydropyridines
AU695348B2 (en) The manufacture of levobupivacaine and analogues thereof from L-lysine
DE60002303D1 (de) Verfahren zur herstellung von paroxetin
JP2771257B2 (ja) イミダゾール誘導体の製法
GB2050375A (en) 4-Cyanophenyl-1,4- dihydropyridine compound, processes for preparation thereof and pharmaceutical composition comprising the same
RU2003129889A (ru) Применение диоксида тиолутина и его производных для получения лекарственного препарата и способ его получения

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20090429